BioCentury
ARTICLE | Company News

FDA grants ponatinib Priority Review

October 25, 2012 12:29 AM UTC

FDA accepted and granted Priority Review to an NDA from Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) for ponatinib to treat resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chro...